Datavault AI Inc. (DVLT)
Stock analysis · NASDAQ · Technology · Software - Infrastructure
Datavault AI Inc. (DVLT) is a publicly traded company in the Technology sector. Latest price: $0.07. Market cap $61.51M. Trailing PE -0.13. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →You have viewed 10 SEO analysis pages
Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.
Continue with free signup1-Year Price
Earnings
Proprietary Signals
About Datavault AI Inc.
Datavault operates as a data science technology firm, specializing in secure data management within the Web 3.0 environment. Its core expertise spans blockchain integration, artificial intelligence, and innovative approaches to data monetization. The company's unique, patented platform is designed to empower users with the ability to visualize, accurately value, and securely commercialize their data holdings. This robust system is utilized across a range of industries, including but not limited to marketing, real estate, and various government applications.
Valuation
| P/E (TTM) | -0.13× |
|---|---|
| P/S (TTM) | 1.39× |
| P/B | 0.21× |
| P/FCF (TTM) | -0.67× |
| EV / EBITDA | -0.69× |
| EV / Sales | 1.49× |
| Earnings Yield | -331.58% |
| Free Cash Flow Yield | -148.99% |
Fundamentals
| Enterprise Value | $66.31M |
|---|---|
| Revenue (TTM) | $44.36M |
| Net Income (TTM) | -$203.97M |
| Free Cash Flow (TTM) | -$86.87M |
| Net Debt | $4.79M |
| Working Capital | $107.69M |
| Gross Margin | 33.40% |
| Operating Margin | -153.27% |
| Net Margin | -391.06% |
| Return on Equity | -86.37% |
| Return on Invested Capital | -26.60% |
Peers
Recent News
- Datavault AI Stock Crashes — Financials Cannot Be Trusted: What You Need to Know
- Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology L…
- DataMeds Regains Compliance With NASDAQ Listing Standards
- DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap
- Datavault AI Highlights Data Futures Platform Patent Amid Tokenized Stock Exemption
Related
Browse more tickers: sitemap